Advertisement
News
Advertisement

Angeion's Medical Graphics Business Offers Additional Choice of Diffusion Technology

Tue, 02/07/2012 - 12:45am
The Associated Press

/FROM PR NEWSWIRE DALLAS 888-776-3971/

STK NASDAQ-SMALL:ANGN

IN HEA MTC MEQ

SU PDT

TO BUSINESS, HEALTH, AND MEDICAL EDITORS:

Angeion's Medical Graphics Business Offers Additional Choice of

Diffusion Technology

SAINT PAUL, Minn., Feb. 7, 2012 /PRNewswire/ -- Medical Graphics

Corporation, a subsidiary of Angeion Corporation (NASDAQ: ANGN), now

offers hospitals, healthcare clinics and private practices assessing

pulmonary function, Real Time Diffusion (RTDT) based on MultiGas

Technology, delivering rapid measurement, clinically significant

graphic data and immediate results. Known globally for Reference

Standard Gas Chromatography, the MedGraphics@ brand now provides

choice of diffusion technology: both meet or exceed International

guidelines and are verifiable by Hans Rudolph DLco Simulator -

recognized as the Laboratory Quality Control for single-breath

diffusion systems.

"We are delighted to provide our worldwide customers choice between

two superb technologies for single breath assessments further

expanding our cardiorespiratory diagnostic services," said Gregg O.

Lehman, Ph.D., Angeion's President and Chief Executive Officer. "With

our proprietary technology platform and real-time sensor quality

assurance, RTD MultiGas Technology provides accurate, immediate

results, eliminating the need of repeating tests. We believe that the

addition of RTD to our product family will provide access to markets

which MedGraphics@ may have been previously excluded."

For both new and existing customers, RTD MultiGas Technology provides

cost savings in time, consumables and increased quality, allowing

customers to test more patients, with less costs and higher

confidence. RTD MultiGas Technology is available as a diffusion option

for MedGraphics UltimaT PF System and award-winning Platinum Elite

Series Body Plethysmograph (body box).

MedGraphics systems provide essential clinical information to

healthcare professionals through non-invasive cardiopulmonary

assessment to improve care of patients in leading hospitals, clinics,

and physician offices throughout the U.S. and in more than 75

countries.

MedGraphics portfolio includes:

-- Pulmonary function from simple spirometry tests (breath flow and

volume) to plethysmography for advanced diagnostic assessments;

-- Exercise assessment in rehabilitation and therapeutic monitoring

centers for evaluating respiratory and cardiac capacity to perform

activities of daily living; and

-- Indirect Calorimetry combined with respiratory measurements to

determine essential nutritional requirements for patients in critical

care/cardiac units.

MedGraphics products incorporate information management and

connectivity solutions for electronic medical record systems to

improve workflow and enhance data access.

About Angeion Corporation Founded in 1986, Angeion Corporation

acquired Medical Graphics Corporation in December 1999. Medical

Graphics develops, manufactures and markets non-invasive

cardiorespiratory diagnostic systems that are sold under the

MedGraphics (www.medgraphics.com) and New Leaf

(www.newleaffitness.com) brand names. These cardiorespiratory product

lines provide solutions for disease detection, integrated care, and

wellness across the entire spectrum of health - whether managing

chronic illness, promoting fitness, or training for the Olympics. The

Company's products are sold internationally through distributors and

in the United States through a direct sales force that targets heart

and lung specialists located in hospitals, university-based medical

centers, medical clinics and physicians' offices, pharmaceutical

companies, medical device manufacturers, clinical research

organizations, health and fitness clubs, personal training studios,

and other exercise facilities. For more information about Angeion,

visit www.angeion.com.

Forward Looking Statements Press releases and other statements by

Angeion may contain forward-looking statements about Angeion's future

financial results and business prospects that by their nature involve

substantial risks and uncertainties. You can identify these statements

by the use of words such as "anticipate," "believe," "estimate,"

"expect," "project," "intend," "plan," "will," "target," and other

words and terms of similar meaning in connection with any discussion

of future operating or financial performance or business plans or

prospects. Our actual results may differ materially depending on a

variety of factors including: (1) national and worldwide economic and

capital market conditions; (2) continuing cost-containment efforts in

our hospital, clinics, and office market; (3) any changes in the

patterns of medical reimbursement that may result from national

healthcare reform; (4) our ability to successfully operate our

business, including successfully converting our increasing research

and development expenditures into new and improved cardiorespiratory

diagnostic products and services and selling these products and

services under the MedGraphics and New Leaf brand names into existing

and new markets; (5) our success in executing our new strategic plan,

developing new products and entering new markets; (6) our ability to

complete our software development initiatives and migrate our

MedGraphics and New Leaf platforms to a next generation technology;

(7) our ability to maintain our cost structure at a level that is

appropriate to our near to mid-term revenue expectations and that will

enable us to increase revenues and profitability as opportunities

develop; (8) our ability to achieve constant margins for our products

and consistent and predictable operating expenses in light of variable

revenues from our clinical research customers; (9) our ability to

expand our international revenue through our distribution partners and

our Milan, Italy representative branch office; (10) our ability to

successfully defend ourselves from product liability claims related to

our cardiorespiratory diagnostic products and claims associated with

our prior cardiac stimulation products; (11) our ability to defend our

existing intellectual property and obtain protection for intellectual

property we develop in the future; (12) our ability to develop and

maintain an effective system of internal controls and procedures and

disclosure controls and procedures and (13) our dependence on

third-party vendors. Additional information with respect to the risks

and uncertainties faced by the Company may be found in, and the above

discussion is qualified in its entirety by, the other risk factors

that are described from time to time in the Company's Securities and

Exchange Commission reports, including the Annual Report on Form 10-K

for the year ended October 31, 2011.

Contact:

Gregg O. Lehman, Ph.D. Joe Dorame, Robert Blum, Joe Diaz

Angeion Lytham Partners, LLC

Chief Executive Officer and President (602) 889-9700

(651) 484-4874 angn@lythampartners.com

SOURCE Angeion Corporation

-0- 02/07/2012

/Web Site: http://www.angeion.com

(NASDAQ-SMALL:ANGN) /

CO: Angeion Corporation

ST: Minnesota

IN: HEA MTC MEQ

SU: PDT

PRN

-- LA48359 --

0000 02/07/2012 10:00:00 EDT http://www.prnewswire.com

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading